Jason Silvers - 26 Feb 2026 Form 3 Insider Report for Generate Biomedicines, Inc. (GENB)

Role
President & CFO
Signature
/s/ Michael Wolf, Attorney-in-Fact
Issuer symbol
GENB
Transactions as of
26 Feb 2026
Net transactions value
$0
Form type
3
Filing time
26 Feb 2026, 20:50:48 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Silvers Jason President & CFO GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE /s/ Michael Wolf, Attorney-in-Fact 26 Feb 2026 0002109011

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GENB Stock Option (Right to Buy) 26 Feb 2026 Common Stock 874,259 $6.05 Direct F1
holding GENB Stock Option (Right to Buy) 26 Feb 2026 Common Stock 263,331 $7.25 Direct F2
holding GENB Stock Option (Right to Buy) 26 Feb 2026 Common Stock 213,956 $9.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option vested on July 25, 2023 with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 The shares underlying this option vest in sixteen equal quarterly installments following March 1, 2024, subject to the Reporting Person's continued service on each such vesting date.
F3 25% of the shares underlying this option shall vest on March 1, 2026 with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney